Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 3/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4456625 | 1.00 | CA12 (0.55) | CA12CA1CA2CA9SIRT2 | |
| SCHEMBL4035564 | 0.88 | CTSL (0.52) | CA12CA1CA2CA9SIRT2 | |
| SCHEMBL4035562 | 0.88 | CTSL (0.52) | CA12CA1CA2CA9SIRT2 | |
| SCHEMBL8346395 | 0.87 | SIRT2 (0.52) | SIRT2SIRT1CASP1PPARGPPARA | |
| SCHEMBL7349434 | 0.86 | CA12 (0.57) | CA12CA1CA2CA9CASP1 | |
| SCHEMBL9686663 | 0.86 | CA12 (0.57) | CA12CA1CA2CA9CASP1 | |
| SCHEMBL13599756 | 0.86 | CTSS (0.55) | CA12CA1CA2CA9SIRT2 | |
| SCHEMBL13599757 | 0.85 | CTSS (0.54) | CA12CA1CA2CA9SIRT2 | |
| SCHEMBL265783 | 0.83 | CTSK (0.66) | SIRT2SIRT1PPARGPPARACTSL | |
| SCHEMBL329038 | 0.83 | CTSK (0.66) | SIRT2SIRT1PPARGPPARACTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312260-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2009-12-17 | — | — | US | disclosed |
| US-5629406-A | AMINO ACID DERIVATIVES | SANKYO COMPANY, LIMITED (JP) | 1997-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312260-A1 | DRUG THERAPY FOR CELIAC SPRUE | SI, DNPEP, SPINT2 | CA12 346/4885CA1 360/4885CA2 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.